Management of Repatha (Evolocumab) Injection Site Reactions
Most injection site reactions to Repatha are mild and self-limited, requiring only reassurance and symptomatic treatment with cold compresses or oral antihistamines if needed—continuation of therapy is appropriate in the vast majority of cases.
Incidence and Characteristics
Injection site reactions occur in approximately 2.1% of patients treated with evolocumab compared to 1.6% with placebo 1, 2. Importantly, 90% of these reactions are considered mild, and only 0.1% of patients discontinue treatment because of injection site reactions 2, 3. These reactions typically manifest as:
- Erythema (redness)
- Swelling
- Pain or tenderness
- Pruritus (itching)
Management Algorithm
For Mild Reactions (Grade 1-2)
Continue evolocumab therapy while implementing the following measures:
- Apply cold compresses to the injection site for 10-15 minutes after injection
- Oral antihistamines (e.g., diphenhydramine 25-50 mg or cetirizine 10 mg) for pruritus if needed
- Rotate injection sites systematically between abdomen, thigh, and upper arm 4
- Avoid areas with scars, stretch marks, or where skin is tender, bruised, red, or hard 4
- Patient education on proper injection technique—ensure the medication reaches room temperature before injection (within 30 days of refrigerator removal) 4
For Serious Hypersensitivity Reactions
Discontinue evolocumab immediately if signs of serious hypersensitivity occur 1:
- Angioedema
- Anaphylaxis
- Severe urticaria
- Bronchospasm
- Systemic symptoms
Treat according to standard of care with epinephrine, antihistamines, and corticosteroids as appropriate, and monitor until symptoms resolve 1. This is a contraindication to future use 1, 4.
Key Clinical Distinctions
Critical pitfall: Do not confuse mild local injection site reactions with true hypersensitivity reactions. The former are not immunologically mediated in most cases and do not predict development of antidrug antibodies or loss of efficacy 5. Unnecessary discontinuation of evolocumab for mild injection site reactions deprives patients of significant cardiovascular benefit—evolocumab reduces major cardiovascular events by 15-20% in high-risk patients 2, 3.
Prevention Strategies
- Proper injection technique training is essential 4
- Allow medication to reach room temperature naturally (do not heat) 4
- Use a different injection site for each dose 4
- Consider the latex-free formulation for latex-sensitive patients, as some presentations contain dry natural rubber in the needle cover 1, 4
Long-term Safety
With median follow-up extending to 8.4 years in open-label extension studies, injection site reactions remain mild and infrequent, with no cumulative toxicity or increased severity over time 6, 7. The cardiovascular benefits of evolocumab substantially outweigh the minor inconvenience of mild injection site reactions in the overwhelming majority of patients.